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ABSTRACT
New forms of evidence are needed to complement evidence generated from ran-
domised controlled trials (RCTs). Real-World Evidence (RWE) is a potential new 
form of evidence, but remains undefined. 
This paper sets to fill that gap by defining RWE as the output from a rigorous 
research process which: (1) includes a clear a priori statement of a hypothesis to be 
tested or research question to be answered; (2) defines the data sources that will 
be used and critically appraises their strengths and weaknesses; and (3) applies 
appropriate methods, including advanced analytics. These elements should be set 
out in advance of the study commencing, ideally in a published protocol. 
The strengths of RWE studies are that they are more inclusive than RCTs and can 
enable an evidence base to be developed around real-world effectiveness and to 
start to address the complications of managing other real-world problems such as 
multimorbidity. Computerised medical record systems and big data provide a rich 
source of data for RWE studies.
However, guidance is needed to help assess the rigour of RWE studies so that the 
strength of recommendations based on their output can be determined. Additionally, 
RWE advanced analytics methods need better categorisation and validation. 
We predict that the core role of RCTs will shift towards assessing safety and achiev-
ing regulatory compliance. RWE studies, notwithstanding their limitations, may 
become established as the best vehicle to assess efficacy. 
Keywords: computerized, data collection, epidemiological methods, evidence-
based practice, health services research, medical record systems, real-world 
analytics,research design, statistics as topic 
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INTRODUCTION
New ways are needed to generate evidence in addition to 
 conducting randomised controlled trials (RCTs).1, 2 This is par-
ticularly so as medicine struggles to understand how to apply 
an evidence base developed for single conditions to an  ageing 
population with multimorbidity.3 Studies using Real-World 
Evidence (RWE) are a potential next step (Box 1). 
Box 1 Definition of RWE 
RWE:
 • Is a form of evidence (along with RCTs, health 
economics studies, etc.) generated to answer a 
question or test a hypothesis
 • Is derived from primary or secondary real-world 
data (RWD) sources, often data from computerised 
medical record (CMR) systems
 • Includes appropriate and rigorous design and 
analyses, generally set out in a protocol in advance 
of conducting the study
 • Provides evidence about patient populations 
diseases, medicines, and health care that will 
inform clinical practice
 • Generates further research questions
Patients, providers and payers all need evidence beyond that 
generated in clinical trials: 
 • Patients want to know to what extent health 
interventions work in the real world for patients like 
them; 
 • Providers of health care want to make more informed 
recommendations for patients; 
 • Commissioners and payers need to know how 
interventions work in their populations in the real 
world; 
 • Society needs to be informed of any long-term 
unexpected complications of therapies.
RWE is enabled by the ubiquity of health care information 
technology systems and the resultant increase in health care 
data that is born digital, as well as by advances in analytics. 
The move towards greater use of RWE is also driven by 
the general shift in health care from a transactional, fee-for-
service model to a more value-based system with payments 
based on outcomes.4 
In summary, RWE is a form of evidence generated by 
applying a research question or testing a hypothesis using 
real-world data (RWD), and applying a method that gen-
erally includes advanced analytics to generate evidence 
(Figure 1).
REAL-WORLD DATA (RWD)
RWD is either primary – collected specifically for the RWE 
study – or secondary use of data collected primarily for 
another purpose (Box 2). All these data have strengths and 
limitations5 that need to be set out in full. 
Box 2 Primary and secondary real-world data (RWD) 
Primary sources of RWD
 • Prospective patient 
registries




 • Pragmatic clinical trials
 • Patient and caregiver 
surveys
 • Hybrid studies (e.g. 
retrospective database 
+ survey)
Secondary sources of RWD
 • Retrospective 
databases/patient 
registries
 • Electronic medical 
records
 • Administrative claim 
records
 • Personal health records
 • Genetic and biomarker 
databanks
 • Patient-derived data 
(via web-based or  
smart technologies










Figure 1. RWE is generated by applying a question or testing a hypothesis using RWD and applying analytical techniques 
set out in the study design
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prospective investigations. RWE studies include people with 
multimorbidity, on usual prescribed doses and with standard 
patterns of adherence. Also, adverse effects of medication 
may be detected in RWE studies.
RWE studies use a larger sample size: whilst important RCTs 
might have thousands of subjects, RWE studies might use a 
million. Exclusion criteria for RCTs are often extensive and limit 
generalisablity; RWE studies can use data that are statistically 
generalisable. RWE studies may particularly lend themselves 
to areas where case definition and outcomes might be readily 
measured from routine data. RWE is able to gain insights from 
complex patients with multimorbidities. The way an interven-
tion is implemented in the ‘real world’ is not necessarily the 
same as the way that intervention was planned to be. 
Data from CMR systems and administrative claims records 
are a mainstay of such studies. Importantly, records can be 
used to rapidly identify any unexpected harms and ensure 
patient safety. And, because of their observational nature, 
there is no need for subjects of such studies to specially 
attend clinics or clinical research centres beyond that is 
required for their routine care.
LIMITATIONS OF RWE
The primary limitation of RWE is that as it is a new and emerg-
ing approach, there is no agreed upon guidance for RWE 
methodologies and evaluation. There is uncertainty about 
Computerised medical record (CMR) systems have been a 
key enabler of RWE investigations, particularly in health sys-
tems where individuals have a unique ID and can be followed 
over time. 5,6 However, access to RWD is not always straight-
forward – and laws and policies to protect privacy can be a 
greater limitation on the ability to carry out RWE research 
than conducting analyses. 
Design of RWE studies
The design used in an RWE study needs to have rigour 
appropriate to the disciplines it is drawn from. Table 1 sets 
out the possible elements of an RWE observational study. 
They should have written, published protocols, and peer-
reviewed outputs.
REAL-WORLD ANALYTICS
Advanced analytic methodologies are used to mine RWD and 
provide evidence for populations and subgroups. Whereas 
trials and conventional evidence inform how populations 
might respond to treatment, RWE looks to provide evidence 
for subgroups and eventually for individuals. 
Strengths of RWE
RWE studies are likely to cost much less than RCTs, and 
retrospective RWE investigations can be completed much 
faster than RCTs – and the same may be true of some 
Table 1. The design of RWE studies
Element of RWE study Design of an RWE observational study
Subjects •	 Includes those eligible for care from the health system
•	 Clinical	topics	where	case	finding	and	outcomes	are	measured	using	routine	data	
•	 Large number of cases 
•	 Case	definition	will	be	that	of	usual	practice
•	 Wide range of other therapies and co-morbidities
•	 Few inclusion/exclusion criteria
Setting •	 Routine care
•	 Range of treatment pathways
•	 Comprehensive use of computerised medical records, across the care pathway
•	 Need to infer meaning from ‘messy’ routine data
Intervention/exposure •	 Prospective (including pragmatic RCTs) and retrospective studies are possible
•	 Open label/neither clinician nor patient will be blinded
•	 May be over a long period of time
•	 That delivered as part of usual care/generally no additional visits
•	 Standard patterns of adherence, no attempts to change beyond those that are part 
of routine care 
Outcome measure •	 Defined	from	routine	data
•	 Loss to follow-up of those who move out of area/out of system
•	 Avoids recall bias
•	 Can include health economic impact
Comparator group •	 Differences in exposure
•	 From different localities
•	 Before and after
•	 Stepped introduction of programme
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taken from hypothesis to creating evidence and uncertainty 
about the relevance of trial results to an ageing population 
with multimorbidity. RCTs in the therapeutic world are short – 
mainly because that is all that regulators require. As a result, 
rare complications of therapies may not be picked up in a trial 
that lasts 6–12 months. This is a very important function of 
RWE or post-marketing studies,  i.e. the detection of unusual 
but significant drug-related issues –either on target or off tar-
get. It is it not just the size of the numerator that is important but 
the possibility of tracking large numbers of patients over long 
periods that provides such useful information. Whilst RWE will 
most often not prove causality, it does enable a hypothesis 
to be raised and explored further. The potential advantages 
of using RWE are that costs are potentially much lower and 
retrospective RWE investigations can take place much faster, 
and the same may be true of some prospective investigations. 
Whilst RWD are inherently more messy, their advantage is that 
RWE studies will include people with multimorbidity, on usual 
prescribed doses, and standard patterns of adherence. Also, 
adverse effects of medication may not always be detected in 
the initial trials.18,19 
CALL FOR THE ESTABLISHMENT OF RWE 
CENTRES
Notwithstanding these limitations, studies using RWE are 
probably here to stay; the urgent need is for methods to 
assess the quality of these studies. Unless we develop robust 
ways of working, RWE might be dismissed as just another 
attempt to create new ways to conduct comparative effec-
tiveness research.20 Research funders should be sponsoring 
the development of RWE centres to develop methodologies 
and conduct RWE studies. Prospective RWE studies could 
focus on stratified medicine.21 These studies should look to 
understand which groups of patients therapeutic interventions 
fit with trial evidence and for which groups they are more or 
less effective in real-world use. Retrospective studies can rap-
idly answer questions about adherence, thresholds at which 
treatments are implemented, unanticipated safety issues, and 
other important questions. They should inform health services 
about the cost-effectiveness of different care pathway options; 
currently, they are often dealt with piecemeal.
sample size, what represents a valid and reliable method, 
how to compare care pathways, especially in people with 
complex health needs, the best method for economic evalua-
tion, and how to reduce bias. A recent debate around possible 
harms of screening for lung cancer reflects this uncertainty.7 
Guidance from the Enhancing the Quality and Transparency 
of health Research network (http://www.equator-network.
org/), notably Consolidated Standards of Reporting Trials, 
informs whether an RCT is of quality. However, despite all 
attempts to reduce the risk of bias, there are concerns that 
funding source may bias trial results,8,9 though there is not 
a consensus about this.10,11 The International Society for 
Pharmacoeconomics and Outcomes Research has to some 
extent sought to address this gap,12 though this does not 
address the study of RWE per se. 
The RWD used in RWE studies are messy and often 
incomplete; sophisticated statistical methods must be used 
to rigorously gain accurate RWE insights. Further, apparently 
easy to define conditions can actually be more complex – 
diabetes provides a good example of this.13 Pitfalls in case 
selection are all too easy and can only be detected if coding 
lists used in analysis are published.14 Case finding if it is to 
be reliable between different brands of computer system – let 
alone international – needs to be much more ontological15,16 
(i.e. transparent models that link clinical concept to coding 
lists used to identify cases, outcomes, confounders, etc.).17 
RWE IS COMPLEMENTARY TO RCT 
EVIDENCE
Whilst the RCT remains the gold standard for testing hypoth-
eses about treatment, other forms of evidence are needed, as 
RCTs fail to answer questions of benefit for those excluded 
from trials. RCTs will always be needed and form an important 
part of the licencing of medications; it is important that they are 
demonstrated to be effective in the core target group who will 
receive them. However, a number of factors suggest that whilst 
RCTs will always be required, a first response of ‘Let’s do a 
trial’ to test a hypothesis, particularly about the effectiveness 
of treatments in clinical practice, should be accompanied by 
a careful evaluation as to whether an RCT is the best option. 
Downsides of RCTs (Figure 2) include high costs, the time 
Limitations of RCTs
Potential advantages of RWEHigh Cost
Long lead times
Challenge for patients
Relevance to real-world practice
of: exposure to intervention,
adherence,
Low Cost
Potentially faster (especially if
retrospective)
No special attendance needed
Exposure to intervention &
monitoring reflects real-world use
Figure 2. The case for increasing the use of RWE
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relative ‘values’ on novel medications, in cash-limited 
health services.24
There are enormous opportunities for the informatics commu-
nity if these predictions about the future research direction are 
correct. The future research landscape will be one in which 
RCTs are required for regulation and for approval of therapies, 
devices, and other interventions. RCTs are needed primarily 
to demonstrate comparative efficacy and safety in a controlled 
environment. RWE studies will become the norm for demon-
strating effectiveness and cost-effectiveness, particularly in the 
context of an ageing population with multimorbidity. 
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RWE studies are needed to properly assess benefit/risk of 
treatments when used in standard clinical practice. CMR can 
facilitate concurrent safety monitoring and data collection 
without direct patient contact and enable large randomised 
study populations to be identified for pragmatic RCTs. 
Informaticians or investigators with a detailed understanding 
of the strengths and weaknesses of routine data – how to 
infer meaning and to avoid pitfalls – should lead such study 
teams. Ensuring privacy and ethical use of patient data is 
also essential for the success of these projects. Analysis of 
health data needs to take place within a secure environment. 
There needs to be a high level of trust alongside profession-
alism in protecting privacy.22,23
New et al. sum up the current situation and the need for RWE:
RCTs are the gold standard but additional information is 
needed about the risk/benefit profile of new treatments 
in real-world practice, and especially evidence providing 
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